← Back
$KRYS All transactions

Krystal Biotech, Inc.

▼ SELL 10b5-1 Plan

$ Value

$539K

Shares

2,043

Price

$264

Filed

Mar 6

Insider

Name

Krishnan Krish S

Title

President and CEO

CIK

0001298709

Roles

Director Officer 10% Owner

Transaction Details

Transaction Date

2026-03-04

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

1,487,410

Footnotes

The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. | The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. | The transaction was executed in multiple trades ranging from $256.81 to $257.75. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. | The transaction was executed in multiple trades ranging from $257.89 to $258.765. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. | The transaction was executed in multiple trades ranging from $259.07 to $260.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. | The transaction was executed in multiple trades ranging from $260.07 to $261.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. | The transaction was executed in multiple trades ranging from $261.07 to $262.04. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. | The transaction was executed in multiple trades ranging from $262.08 to $263. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. | The transaction was executed in multiple trades ranging from $263.19 to $264.1. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. | The transaction was executed in multiple trades ranging from $264.2 to $265.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. | The transaction was executed in multiple trades ranging from $265.235 to $266.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. | The transaction was executed in multiple trades ranging from $266.36 to $266.93. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. | Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control, and holdings and transactions by the Krishnan Family Trust are also reflected on the separate Form 4 filed by his spouse.

Filing Info

Accession No.

0001298709-26-000004

Form Type

4

Issuer CIK

0001711279

Krishnan Krish S's History

Date Ticker Type Value
2026-03-04 KRYS $124K
2026-03-04 KRYS $121K
2026-03-04 KRYS $358K
2026-03-04 KRYS $815K
2026-03-04 KRYS $774K
2026-03-04 KRYS $625K
2026-03-04 KRYS $539K
2026-03-04 KRYS $2.3M
2026-03-04 KRYS $648K
2026-03-04 KRYS $245K

Other Insiders at KRYS (90d)

Insider Bought Sold Last
JANNEY DANIEL $19.4M 2026-02-27
ROSSI DINO A $5.0M 2026-02-19
Krishnan Krish S
President and CEO
$6.0M 2026-03-04
Krishnan Suma
President, R&D
$6.6M 2026-03-04
ROMANO KATHRYN
Chief Accounting Officer
$3.6M 2026-03-02